2025
Gastrointestinal oncologic emergencies: a radiologists’ guide
Wang M, Furrow M, Gao M, Nasrullah A, Shehata M, Shaaban A, Shenoy-Bhangle A, Revzin M, Katz D, Elsayes K. Gastrointestinal oncologic emergencies: a radiologists’ guide. Abdominal Radiology 2025, 1-11. PMID: 40464849, DOI: 10.1007/s00261-025-05012-9.Peer-Reviewed Original ResearchOncologic emergencyAirway-esophageal fistulaLife-threatening conditionPrevalence of cancerCancer related complicationsTreatment related effectsUnderlying malignancyIntestinal perforationSystemic manifestationsImaging manifestationsGastrointestinal bleedingRelated complicationsIntestinal ischemiaIntestinal obstructionCancer stageCancer patientsBowel changesGastrointestinal systemCancerMalignancyReview articleFistulaBleedingMetastasisComplications
2024
Acute Hepatitis due to Primary Human Immunodeficiency Virus Infection
Elliott E, Smith D, Lipscomb J, Banini B, Meurer L, Vanderford T, Johnson J, Jain D, Achhra A. Acute Hepatitis due to Primary Human Immunodeficiency Virus Infection. Open Forum Infectious Diseases 2024, 11: ofae170. PMID: 38585186, PMCID: PMC10996125, DOI: 10.1093/ofid/ofae170.Peer-Reviewed Original ResearchHuman immunodeficiency virusHuman immunodeficiency virus infectionAcute hepatitisPrimary human immunodeficiency virus infectionConsistent with acute hepatitisPrimary human immunodeficiency virusHuman immunodeficiency virus p24 antigenAcute retroviral syndromeImmunodeficiency virus infectionSevere acute hepatitisHIV proviral DNAAcute liver diseaseP24 antigenImmunodeficiency virusLaboratory abnormalitiesSystemic manifestationsRare caseLiver diseaseProviral DNAVirus infectionLiver histopathologyHepatitisCell compartmentParenchymal cellsLiver tissueEmbracing cancer complexity: Hallmarks of systemic disease
Swanton C, Bernard E, Abbosh C, André F, Auwerx J, Balmain A, Bar-Sagi D, Bernards R, Bullman S, DeGregori J, Elliott C, Erez A, Evan G, Febbraio M, Hidalgo A, Jamal-Hanjani M, Joyce J, Kaiser M, Lamia K, Locasale J, Loi S, Malanchi I, Merad M, Musgrave K, Patel K, Quezada S, Wargo J, Weeraratna A, White E, Winkler F, Wood J, Vousden K, Hanahan D. Embracing cancer complexity: Hallmarks of systemic disease. Cell 2024, 187: 1589-1616. PMID: 38552609, PMCID: PMC12077170, DOI: 10.1016/j.cell.2024.02.009.Peer-Reviewed Original ResearchConceptsHuman genetic variationSystemic diseaseHallmarks of cancerTumor-related thrombosisGenetic variationGene-environment interactionsCancer-related deathsComplexity of cancerMolecular basisTreat human cancersNervous system interactionsMechanisms of carcinogenesisHuman cancersImprove patient qualityCancer cachexiaSystemic manifestationsTumor micro-Cancer outcomesDistant organsTumor initiationMolecular oncologyTumorPatients' qualityPrevent cancerCancer
2023
Pediatric Lupus Retinopathy: A Rare Manifestation of a Grave Systemic Disorder
Parakh S, Bhatt V, Das S, Chaturvedi A, Luthra G, Katoch D, Barman P, Jindal A, Luthra S. Pediatric Lupus Retinopathy: A Rare Manifestation of a Grave Systemic Disorder. Cureus 2023, 15: e46616. PMID: 37937017, PMCID: PMC10626398, DOI: 10.7759/cureus.46616.Peer-Reviewed Original ResearchPediatric systemic lupus erythematosusAntinuclear antibodiesBilateral diminution of visionAnti-extractable nuclear antigenCases of pediatric systemic lupus erythematosusDiminution of visionActive systemic diseasePositive serum antinuclear antibodySerum antinuclear antibodiesSystemic lupus erythematosusMacular edemaRetinal vasculitisOcular manifestationsLaser photocoagulationTopical steroidsLupus retinopathySystemic immunosuppressionRare manifestationSystemic manifestationsLupus erythematosusRare caseClinical examinationSystemic diseaseMalar regionNuclear antigen
2022
Systemic Manifestations of Gastrointestinal Tract Diseases and Systemic Diseases Involving the Gastrointestinal Tract
Patel N, Das P, Jain D. Systemic Manifestations of Gastrointestinal Tract Diseases and Systemic Diseases Involving the Gastrointestinal Tract. 2022, 521-572. DOI: 10.1007/978-981-16-6395-6_14.Peer-Reviewed Original ResearchExtraintestinal manifestationsGastrointestinal disordersSystemic diseaseGastrointestinal tractPrimary gastrointestinal disordersCommon gastrointestinal disorderInflammatory bowel diseaseCommon systemic diseasesGastrointestinal tract diseaseGastrointestinal symptomsBowel diseaseRenal diseaseSystemic manifestationsVasculitic disordersWhipple's diseaseSystemic disordersVascular diseaseCeliac diseaseGastrointestinal infectionsTract diseasePathogenetic mechanismsPolyposis syndromeGastrointestinal diseasesPancreatic diseaseDisease
2021
Novel and Emerging Therapies for Inflammatory Bowel Disease
Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Frontiers In Pharmacology 2021, 12: 651415. PMID: 33935763, PMCID: PMC8080036, DOI: 10.3389/fphar.2021.651415.BooksInflammatory bowel diseaseBowel diseaseAnti-tumor necrosis factorPotential systemic manifestationsSecondary treatment failureTreatment response ratesJanus kinase inhibitorSelective Janus kinase inhibitorNew therapeutic targetsEmerging TherapiesCurrent biologicsIntestinal inflammationSystemic manifestationsUlcerative colitisCrohn's diseaseTreatment failureSafety profileNecrosis factorTherapeutic targetResponse rateDiseaseKinase inhibitorsTarget agentsInhibitorsTolerability
2020
Thoracic aortic aneurysm gene dictionary
Rohde S, Zafar MA, Ziganshin BA, Elefteriades JA. Thoracic aortic aneurysm gene dictionary. Asian Cardiovascular And Thoracic Annals 2020, 29: 682-696. PMID: 32689806, DOI: 10.1177/0218492320943800.Peer-Reviewed Original ResearchConceptsThoracic aortic aneurysmAortic aneurysmRisk of dissectionSpecific causative mutationSmaller aortic sizeSystemic manifestationsAortic sizeDissection patientsLethal complicationGenetic predispositionProgressive enlargementAneurysmsNatural historyPersonalized careAneurysm growthPatientsFamilial casesClinical realityDissectionNon-syndromic thoracic aortic aneurysmsSubstantial proportionGenetic sequencingDisease phenotypeCausative genesHigh rateElagolix in the treatment of endometriosis: impact beyond pain symptoms
Archer DF, Soliman AM, Agarwal SK, Taylor HS. Elagolix in the treatment of endometriosis: impact beyond pain symptoms. Therapeutic Advances In Reproductive Health 2020, 14: 2633494120964517. PMID: 33294846, PMCID: PMC7708701, DOI: 10.1177/2633494120964517.Peer-Reviewed Original ResearchPain symptomsSystemic manifestationsOral gonadotropin-releasing hormone receptor antagonistGonadotropin-releasing hormone receptor antagonistTreatment of endometriosisHormone receptor antagonistQuality of lifePelvic painSevere painCommon symptomsReceptor antagonistEndometriosisElagolixBeneficial effectsSymptomsPainManifestationsOutcomesPatientsWorkplace effectsAntagonistDiseaseWomen
2016
Ocular Manifestations of Inherited Phospholipase-C&ggr;2–Associated Antibody Deficiency and Immune Dysregulation
Di Zazzo A, Tahvildari M, Florakis G, Dana R. Ocular Manifestations of Inherited Phospholipase-C&ggr;2–Associated Antibody Deficiency and Immune Dysregulation. Cornea 2016, 35: 1656-1657. PMID: 27442322, PMCID: PMC5250612, DOI: 10.1097/ico.0000000000000951.Peer-Reviewed Original ResearchConceptsOcular manifestationsOcular surfaceAntibody deficiencyImmune dysregulationEpisodes of ocular inflammationInterleukin-1Anti-IL-1 therapySystemic immunomodulatory treatmentSystemic side effectsBouts of inflammationInterstitial lung diseaseRecurrent inflammatory diseaseInterleukin-1 productionCorneal pannusCorneal involvementCorneal scarringOcular inflammationOral prednisoneOcular symptomsSystemic immunosuppressionImmunomodulatory treatmentSystemic manifestationsLung diseaseActive lesionsPartial improvementThe association between systemic sclerosis disease manifestations and esophageal high‐resolution manometry parameters
Kimmel JN, Carlson DA, Hinchcliff M, Carns MA, Aren KA, Lee J, Pandolfino JE. The association between systemic sclerosis disease manifestations and esophageal high‐resolution manometry parameters. Neurogastroenterology & Motility 2016, 28: 1157-1165. PMID: 26921101, PMCID: PMC4956560, DOI: 10.1111/nmo.12813.Peer-Reviewed Original ResearchConceptsHigh-resolution manometrySSc disease durationClinical characteristicsMotility diagnosisNormal motilityHigh-resolution manometry parametersSevere esophageal dysfunctionWorse lung functionIneffective esophageal motilityPulmonary function testsRetrospective chart reviewRodnan skin scoreSkin disease severitySymptoms of dysphagiaAbsent contractilityEsophageal dysfunctionChart reviewSkin involvementSSc patientsLung functionSkin scoreSystemic manifestationsSystemic sclerosisEsophageal contractilityEsophageal motility
2015
Synchronous pulmonary malignancies: atypical presentation of mantle cell lymphoma masking a lung malignancy
Masha L, Zinchuk A, Boosalis V. Synchronous pulmonary malignancies: atypical presentation of mantle cell lymphoma masking a lung malignancy. Rare Tumors 2015, 7: 5929. PMID: 26500732, PMCID: PMC4600994, DOI: 10.4081/rt.2015.5929.Peer-Reviewed Case Reports and Technical NotesMantle cell lymphomaCell lymphomaAtypical presentationLarge pleural effusionAtypical epithelial cellsLung primaryLung malignancySystemic manifestationsPleural effusionPleural biopsyUndifferentiated carcinomaNew diagnosisLymphomaMalignancyEpithelial cellsPatientsPresentationChemotherapyBiopsyCarcinomaEffusionLymphocytesClonal populationsDiagnosis
2014
Systemic Manifestations and Comorbidities of Chronic Obstructive Pulmonary Disease
Most J, Possick J, Rochester C. Systemic Manifestations and Comorbidities of Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine 2014, 21: 155-166. DOI: 10.1097/cpm.0000000000000044.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseSystemic inflammationPulmonary diseaseMore health care resourcesGastroesophageal reflux diseaseObstructive sleep apneaSkeletal muscle dysfunctionHealth care resourcesQuality of lifeCOPD patientsReflux diseaseRenal insufficiencyCommon comorbiditiesSystemic manifestationsMuscle dysfunctionSleep apneaFunctional statusLung cancerChronic infectionChronic diseasesCardiovascular diseaseComorbiditiesHigh riskCare resources
2013
Cystic Kidney Disease in a Patient With Systemic Toxicity From Long-term d-Penicillamine Use
Koraishy FM, Cohen RA, Israel GM, Dahl NK. Cystic Kidney Disease in a Patient With Systemic Toxicity From Long-term d-Penicillamine Use. American Journal Of Kidney Diseases 2013, 62: 806-809. PMID: 23796907, DOI: 10.1053/j.ajkd.2013.04.017.Peer-Reviewed Original ResearchConceptsCystic kidney diseaseKidney diseaseKidney injuryD-penicillamineLong-term d-penicillamine therapyD-penicillamine therapyD-penicillamine toxicityAcute kidney injuryD-penicillamine treatmentEvidence of cystsElastosis perforans serpiginosaTreatment of cystinuriaImpaired repair processMultiorgan manifestationsSystemic manifestationsKidney functionMembranous glomerulonephritisSkin findingsGlomerular abnormalitiesRenal imagingCollagen depositionSystemic toxicityPatientsCyst formationDisease
2012
A renal variant of Fabry disease: A case with a novel Gal A hemizygote mutation.
H Mukdsi J, Gutiérrez S, Barrón B, Novoa P, Fernández S, de Diller AB, I Torres A, Formica RN, Orías M. A renal variant of Fabry disease: A case with a novel Gal A hemizygote mutation. Journal Of Nephropathology 2012, 1: 194-7. PMID: 24475416, PMCID: PMC3886146, DOI: 10.5812/nephropathol.8123.Peer-Reviewed Case Reports and Technical NotesFabry diseaseRenal variantLong-term followProgressive kidney diseaseYear old manEnzyme replacement therapyΑ-GalA activityRecessive inborn errorPodocyte activationSecond biopsySystemic manifestationsKidney diseaseReplacement therapyHistologic dataDirect DNA sequencingGenetic testingDeficient activityDiseaseElectron microscopic evidenceInborn errorsTherapy treatmentGlycosphingolipid metabolismGene mutationsHemizygote mutationIntracellular inclusions
1989
Catatonic syndrome caused by autoimmune disease: spontaneous remission.
Lichtenstein A, Calish I, Oliveira R, Miguel Filho E, Rocha A. Catatonic syndrome caused by autoimmune disease: spontaneous remission. Clinics 1989, 44: 312-5. PMID: 2486424.Peer-Reviewed Original ResearchConceptsCSF immune complexesAutoimmune diseasesImmune complexesCatatonic syndromeCerebrospinal fluidPositive antinuclear factorSystemic lupus erythematosusAntinuclear factorLupus erythematosusRare manifestationSystemic involvementSystemic manifestationsSpontaneous remissionImmunosuppressive drugsPsychiatric manifestationsCatatonic patientsImmunologic testsCase reportMetabolic disturbancesPsychiatric effectsNucleolar patternSchizophrenic disordersValuable markerDiseasePsychiatric picture
1987
Cytotoxic Factors Secreted by Cells Infected by Human Immunodeficiency Virus Type I
RATNER L, POLMAR S, PAUL N, RUDDLE N. Cytotoxic Factors Secreted by Cells Infected by Human Immunodeficiency Virus Type I. AIDS Research And Human Retroviruses 1987, 3: 147-155. PMID: 3497655, DOI: 10.1089/aid.1987.3.147.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type IVirus type IMononuclear cellsHIV-1Cytotoxic factorPeripheral blood mononuclear cellsHIV-1 infectionBlood mononuclear cellsHIV-1 replicationTumor necrosis factorCell-derived factorCell linesMonocytoid cell linesType ICytotoxic activityAspects of infectionSystemic manifestationsNecrosis factorUninfected counterpartsVirus replicationConditioned mediaCell killingFibroblast cell lineInfectionMurine fibroblast cell line
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply